Women with breast cancer found to have residual invasive disease during surgery after neoadjuvant chemotherapy and HER2-targeted therapy have a significantly worse prognosis. For these patients, the Czech Oncology Society ČLS JEP recommends adjuvant therapy with trastuzumab emtansine based on data from the Katherine clinical study. However, this treatment has not yet been covered by public health insurance, with reimbursement starting from March 1, 2021.
Don‘t have an account? Create new account
Enter the email address that you registered with. We will send you instructions on how to set a new password.
